BofA warns Fed risks policy mistake with early rate cuts
Isaac Paul J, a director at Stereotaxis , Inc. (NYSE:STXS), recently purchased 38,000 shares of the company’s common stock, according to a recent SEC filing. The transaction, dated March 10, 2025, was executed at a price of $1.81 per share, amounting to a total investment of approximately $68,780. The purchase comes as the stock has experienced significant volatility, with shares down over 22% year-to-date and trading near InvestingPro’s calculated Fair Value. Following this acquisition, Paul holds a total of 87,299 shares directly. Additionally, he is associated with Arbiter Partners Capital Management LLC, which beneficially owns a larger stake in Stereotaxis, including shares held in affiliated funds and managed accounts. The medical technology company, currently valued at $153 million, has shown weak financial health according to InvestingPro’s comprehensive analysis, which includes over 30 key financial metrics and exclusive insights available in the Pro Research Report.
In other recent news, Stereotaxis Inc. reported its fourth-quarter 2024 earnings, revealing a revenue of $6.3 million, which did not meet the forecasted $8.08 million. The company also reported an earnings per share (EPS) of -$0.09, missing the expected -$0.06. This marks a 39% year-over-year revenue increase, but the full-year revenue remained flat at $26.9 million. Despite these challenges, Stereotaxis is focusing on expanding its catheter portfolio and launching new products, with anticipated double-digit growth in 2025. Additionally, the company announced two significant FDA submissions for key catheter innovations. Analysts from firms like Lake Street Capital Markets and Piper Sandler engaged in discussions about the company’s strategic direction, including the anticipated approval of the Magic Ablation Catheter in the U.S. in the second half of the year. Stereotaxis is also preparing for the commercial launch of its Genesis X robot in Europe and the U.S., expected in the second half of 2025. The company maintains a strong cash position with $12.4 million in cash and equivalents and no debt.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.